Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration and angiogenesis

Xiaoming Dai¹, Peilu She², Fangtao Chi¹, Ying Feng¹, Huan Liu¹, Daqing Jin², Yiqiang Zhao¹, Xiaocan Guo¹, Dandan Jiang¹, Kun-Liang Guan³, Tao P. Zhong², Bin Zhao¹,*

¹Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China
²State Key Laboratory of Genetic Engineering, Department of Genetics, School of Life Sciences, Fudan University, Shanghai 200433, China
³Department of Pharmacology and Moores Cancer Center, University of California at San Diego, La Jolla, CA 92093-0815

Running title: the Hippo pathway inhibits AMOT in cell migration

*To whom correspondence should be addressed: binzhao@zju.edu.cn

Key words: actin/AMOT/angiogenesis/cell migration/Lats/protein kinases/protein phosphorylation/the Hippo pathway

Background: Substrates of the Hippo pathway kinases Lats1/2 are largely unknown besides YAP/TAZ.

Results: Phosphorylation of angiomotin by Lats1/2 inhibits interaction with F-actin thus impairs cell migration and angiogenesis.

Conclusion: AMOTp130 is a physiological and functional substrate of Lats1/2 and the Hippo pathway.

Significance: Demonstrating how identification of novel substrates would facilitate understanding the physiology of the Hippo pathway.

ABSTRACT

The Hippo tumor suppressor pathway plays important roles in organ size control through Lats1/2 mediated phosphorylation of the YAP/TAZ transcription co-activators. However, YAP/TAZ independent functions of the Hippo pathway are largely unknown. Here we report a novel role of the Hippo pathway in angiogenesis. Angiomotin p130 isoform (AMOTp130) is phosphorylated on a conserved HXRXXS motif by Lats1/2 downstream of GPCR signaling. Phosphorylation disrupts AMOT interaction with F-actin and correlates with reduced F-actin stress fibers and focal adhesions. Furthermore, phosphorylation of AMOT by Lats1/2 inhibits endothelial cell migration in vitro and angiogenesis in zebrafish embryos in vivo. Thus AMOT is a direct substrate of Lats1/2 mediating functions of the Hippo pathway in endothelial cell migration and angiogenesis.

Organ size homeostasis is a remarkable feature of multicellular organisms. In the last decade, the Hippo pathway has been found to play a key role in control of organ size (1-14). At the center stage of this pathway is the Mst1/2-Lats1/2
the Hippo pathway inhibits AMOT in cell migration

kinase cascade. Upstream signals such as cell adhesion, cytoskeleton remodeling, lysophosphatidic acid (LPA) and its respective G-protein coupled receptors (GPCRs) were found to regulate the Hippo pathway (15-23). YAP transcription co-activator and its paralog TAZ are the best known Hippo pathway targets mediating gene expression regulation and organ size control (22,24-27). Nevertheless, the various upstream input signals suggest rich functions of the pathway. Indeed, Lats1/2 were reported to regulate cellular processes such as cell differentiation, cytokinesis, senescence, autophagy, centrosome duplication, and neuron dendritic tiling (28-33). It is unlikely that YAP/TAZ inactivation mediates all these functions. However, YAP/TAZ-independent functions of the Hippo pathway were poorly studied.

Here we report that angiomotin p130 isoform (AMOTp130) is phosphorylated on a conserved HXRXXS motif by Lats1/2 downstream of GPCR signaling. Phosphorylation disrupts AMOT interaction with F-actin and correlates with reduced F-actin stress fibers and focal adhesions. Furthermore, phosphorylation of AMOT by Lats1/2 inhibits endothelial cell migration in vitro and zebrafish embryonic angiogenesis in vivo. These studies identified AMOT as a critical effector of the Hippo pathway downstream of GPCR signaling in regulation of cell migration and angiogenesis.

EXPERIMENTAL PROCEDURES
Antibodies, plasmids, and other materials- We obtained anti-AMOT antibodies from Bethyl Lab; anti-Lats1 and anti-Lats2 from Cell Signaling Technologies; anti-GST from Genscript; anti-α-Tubulin, anti-Flag, and anti-vinculin from Sigma; anti-thiophosphate-ester from Epitomics; anti-HSP90 from BD Biosciences; anti-HA and anti-Myc from Covance; Alexa Fluor 488 or 594 conjugated secondary antibodies and Alexa Fluor 488-phalloidin from Invitrogen; Horseradish peroxidase conjugated secondary antibodies from GE Healthcare. Anti-phosphoAMOTp130 (S175) antibody was generated by immunizing rabbits with phospho-peptide KQGHVRSLS(p)ERL. Human AMOTp130 were subcloned from other vectors into pCMV-Flag, pcDNA3-HA, pGEX-KG and pQCXIH vectors. Human AMOTp80, mouse AMOTL1 and AMOTL2 were subcloned into pcDNA3-HA and pCMV-Flag vectors. Human AMOTp130 mutants were generated by site-directed mutagenesis. Other plasmids were described before (16,22,34). Phos-tag conjugated acrylamide was purchased from Wako Chemicals. All other chemicals were from Sigma.

Cell culture, transfection, and viral infection- HEK293, HEK293T, Cos7, HEK293P, and HUVEC cells were cultured in DMEM (Invitrogen) containing 10% FBS (Invitrogen) and 50μg/ml penicillin/streptomycin (P/S). Transfection with Lipofectamine (Invitrogen) was performed according to the manufacturer’s instructions. For viral infection, HEK293P cells were transfected with viral constructs and packaging plasmids. 48 hours later, viral supernatant was supplemented with 5μg/ml polybrene, filtered through a 0.45μm filter, and used to infect target cells.

Immunoprecipitation and kinase assay- For Lats2 kinase assays, HEK293 cells were transfected with indicated plasmids. 48 hours post-transfection, cells were lysed with lysis buffer (50mM HEPES at pH 7.5, 150mM NaCl, 1mM EDTA, 1% NP-40, 10mM pyrophosphate, 10mM glycerophosphate,
the Hippo pathway inhibits AMOT in cell migration

50mM NaF, 1.5mM Na3VO4, protease inhibitor cocktail (Roche), 1mM DTT, 1mM PMSF) and immunoprecipitated with anti-HA antibody. The immunoprecipitates were washed three times with lysis buffer, once with wash buffer (40mM HEPES, 200mM NaCl) and once with kinase assay buffer (30mM HEPES, 50mM potassium acetate, 5mM MgCl2). The immunoprecipitated Lats2 was subjected to kinase assay in the presence of 500μM ATP or ATP-γ-S and 1μg of recombinant GST-AMOTp130 purified from E. coli as substrates. The reaction mixtures were incubated for 30 min at 30°C. For detection by anti-thiophosphate-ester antibody, the reaction mixtures were further supplemented with 2.5mM PNBM. Alkylation reactions were allowed to proceed for 1 h at room temperature. The reactions were terminated with SDS sample buffer and boiled before analysis by SDS-PAGE.

Actin spin-down assay- Actin Binding Protein Biochem Kit was obtained from Cytoskeleton. The assay was performed following the manufacturer’s instructions. Briefly, F-actin was polymerized and mixed with GST-AMOTp130 proteins purified from E. Coli. The mixture was then centrifuged at 150,000g for 1.5 h at 24 °C. Supernatants and pellets were then collected and processed for electrophoresis. Proteins were visualized by Coomassie Blue staining or Western blots.

Cell migration assay- Cell migration assay was performed using BD Falcon Cell culture inserts for 24-well plates with 8.0μm pore size. Bottom sides of filters were pre-coated with 20 mg/ml fibronectin. HUVEC cells were serum-starved for 12 hr and then seeded into the upper chambers of the inserts at 4x10^4 cells/well in serum-free medium, and lower chambers were filled with serum-free or 10% FBS-containing medium. After 12 hours, cells were stained with 0.5% crystal violet. Cells in upper chambers were carefully removed, and bottom sides of the chambers were pictured.

Immunofluorescence staining- Cells were fixed with 4% paraformaldehyde for 15 min and then permeabilized with 0.1% Triton X-100. Cells may be treated with 100μg/ml digitonin for 5 mins as indicated. After blocking in 2% BSA for 30 min, slides were incubated with first antibody diluted in 1% BSA overnight at 4 °C. After washing with PBS, slides were incubated with Alexa Fluor 488 or 594 conjugated secondary antibodies for 1.5 hours. For staining of F-actin, cells were incubated with Alexa Fluor 488-phalloidin for 1.5h. The slides were then washed and mounted.

RNA interference- Short interfering RNA (siRNA) oligonucleotides toward human Lats1, Lats2, AMOT and control siRNA toward firefly luciferase were transfected into indicated cells using Lipofectamine RNAiMax Reagent (Life Technologies) following the manufacturer’s instructions. Cells were analyzed 72 hours post-transfection.

Zebrafish maintenance and angiogenesis assay- Zebrafish embryos were produced by pairwise matings, raised at 28.5°C and staged as described (35). A transgenic Tg(flk:GFP) line was used in this study (36). Sense-capped mRNAs were synthesized using mMESSAGE mMACHINE system (Ambion) according to the manufacturer’s instructions. Plasmids encoding human AMOTp130, AMOTp130-SA, AMOTp130-SD, mouse Lats2 or Lats2-KR were digested with XhoI and transcribed with T7 polymerase. Poly (A)
tails (Takara Bio Cat. No. 2181) were added to the synthetic mRNAs. Synthesized mRNAs were purified using the MEGAclear Kit (Ambion). Antisense morpholino oligonucleotide AMOT-MO
(5’-CCACTGACACAACTACCACAAAGTG-3’)
(37) was synthesized by Gene Tools, LLC. Synthetic mRNAs and morpholinos were microinjected into zebrafish embryos at the one-two-cell stages as described (38). Injection doses were as following: 8.2ng AMOT-MO; 8.2ng AMOT-MO+400pg hAMOTp130-WT/SA/SD; 5.6ng AMOT-MO+373pg hAMOTp130-WT/SA+80pg mLats2-WT/KR. Vascular phenotypes were imaged using a Zeiss Observer Z1 microscope.

RESULTS

The Hippo pathway phosphorylates AMOT family proteins- The AMOT family proteins localize to specific cellular compartments and regulate cell migration and proliferation (37,39-41). AMOT is a component of the Hippo pathway capable of inhibiting YAP through direct binding and Lats1/2 activation (34,42-44). Surprisingly, we found that Lats2 induced a dramatic electrophoretic mobility shift of AMOTp130 comparable to that of YAP on Phos-tag-containing gels which specifically retards phosphorylated proteins (Fig. 1A). Furthermore, Lats2 also induced dramatic up-shift of other AMOT family proteins AMOTL1 and AMOTL2 (Fig. 1A). The Lats2-induced mobility shift of AMOTp130 was eliminated by treatment of the protein with lambda protein phosphatase (Fig. 1B). In addition, co-transfection of AMOTp130 with other Hippo pathway components Mst2, Sav, Mob, and Lats2 induced AMOTp130 mobility shift in a synergistic manner (Fig. 1C). These experiments indicate that Lats1/2 in the Hippo pathway could induce phosphorylation of AMOT family proteins.

We then examined whether Lats2 could phosphorylate AMOT in vitro. In this assay, the kinase utilizes ATP-γ-S as phosphate donor to generate thiophosphorylated substrate, which in turn reacts with p-nitrobenzyl mesylate (PNBM) to form a thiophosphate-ester (45). As detected by a thiophosphate-ester-specific antibody, recombinant AMOTp130 could be phosphorylated by Lats2 in vitro (Fig. 1D). The phosphorylation is more efficient when Mob and Sav were co-transfected. In contrast, the kinase inactive Lats2-KR could not phosphorylate AMOTp130. Thus, Lats2 phosphorylates AMOTp130 both in vitro and in vivo.

Lats2 phosphorylates AMOT on serine 175-

Previous studies have revealed the optimal Lats1/2 phosphorylation target consensus motif as HXRXXS (22,25). Interestingly, we found one HXRXXS motif, and one HXKXXS motif, also permissive for phosphorylation by Lats1/2, on AMOTp130 (Fig. 2A). Both motifs are conserved in AMOT family members and across species (Fig. 2A). As shown in Fig. 2B, mutation of S175 in the N-terminal motif to alanine largely repressed Lats2-induced up-shift of AMOTp130, suggesting that this reside is phosphorylated by Lats2. Further mutation of S859 eliminates the mild shift of S175A, suggesting that S859 is also phosphorylated by Lats2. However, individual mutation of S859 did not repress the up-shift possibly due to limited sensitivity of the Phos-tag method. The histidine in the HXRXXXS motif is crucial for substrate recognition. Indeed, similar to S175A, mutation of H170 largely abolished AMOTp130 up-shift in response to Lats2 (Fig. 2B). These experiments demonstrate that
phosphorylation of S175 is largely responsible for Lats2-induced up-shift of AMOTp130.

To further confirm that AMOTp130 S175 is indeed phosphorylated by Lats2, we generated an anti-pAMOT (S175) antibody. As expected, this antibody detected phosphorylation of ectopically expressed AMOTp130, which was markedly enhanced by Lats2 co-expression and eliminated by phosphatase treatment (Fig. 2C). Furthermore, AMOTp130 is phosphorylated on S175 by Lats2 but not Lats2-KR \textit{in vitro} (Fig. 2D). Thus, AMOTp130 is phosphorylated on S175 by Lats2 \textit{in vitro} and \textit{in vivo}.

\textit{GPCR signaling inhibits AMOTp130 phosphorylation mediated by the Hippo pathway:} Following identification of the phosphorylation site we further examined the role of the Hippo pathway in physiological regulation of AMOT. Consistent with the inhibition of the Hippo pathway by serum and LPA, these stimulations inhibit endogenous AMOTp130 phosphorylation on S175 (Fig. 2E, 2F). LPA in serum represses the Hippo pathway via activation of GPCRs such as LPAR2, and the coupled G-proteins such as G_{q} and G_{12} (16). Consistently, expression of LPAR2 or active QL mutants of G_{q} or G_{12} potently inhibits endogenous AMOTp130 phosphorylation in serum-deprived cells (Fig. 2G). Furthermore, siRNA knockdown of Lats1 and Lats2 largely eliminates AMOTp130 phosphorylation on S175 in serum-deprived cells (Fig. 2H). Integrity of the actin cytoskeleton is required for GPCR-induced repression of the Hippo pathway (16). Indeed, disruption of F-actin induced AMOTp130 phosphorylation in cells cultured in serum-rich medium (Fig. 2I). Taken together, serum and GPCR signaling regulate AMOTp130 phosphorylation on S175 through Lats1/2 kinases.

\textit{Phosphorylation of AMOTp130 on S175 inhibits its interaction with F-actin:} AMOTp130 is known to colocalize with F-actin in cells dependent on its N-terminal domain containing S175 (46). By immunofluorescence staining, we indeed observed colocalization of ectopically expressed AMOTp130 with F-actin filaments (Fig. 3A). At lower expression level of AMOT, the AMOT-F-actin filaments closely resemble actin stress fibers (Fig. 3A). However, at higher expression level, the filaments are thicker possibly represent AMOT-F-actin filament bundles (Fig. 3A, middle panel). In support of a real stress fiber identity of AMOT-F-actin filaments, they are resistant to digitonin treatment before fixation and are anchored to focal adhesions (Fig. 3B, 3C). Interestingly, expression of Lats2 disrupted the filamentous AMOTp130 and results in diffused and irregular dots-like localization of AMOT (Fig. 3A, 3F). Thus phosphorylation of AMOTp130 on S175 by Lats2 may disrupt AMOT-F-actin interaction. Consistently, the S175A mutant colocalizes with F-actin in a manner insensitive to Lats2 (Fig. 3D, 3F). More strikingly, irrespective to Lats2 expression, the phospho-mimetic S175D mutant exhibited dots-like cytoplasmic localization (Fig. 3E, 3F). Importantly, using two independent antibodies, we demonstrated that endogenous AMOT colocalizes with F-actin in 293T cells (Fig. 4A, 4B, 4D). The filamentous localization of endogenous AMOT is also disrupted by Lats2 in a kinase-dependent manner (Fig. 4C, 4D). These data demonstrate that phosphorylation of AMOTp130 by Lats2 on S175 inhibits AMOTp130-F-actin interaction \textit{in vivo}.

To test the possibility of a direct interaction between AMOTp130 and F-actin we performed \textit{in vitro} F-actin spin-down assay. In this assay,
F-actin binding proteins would co-sediment with pre-polymerized F-actin. We found that addition of F-actin brought all recombinant AMOTp130 or the N-terminal fragment into the pellet fraction indicating direct binding of AMOTp130 to F-actin (Fig. 4E). However, the phospho-mimetic S175D mutant largely remains in the supernatant (Fig. 4E). These results suggest that phosphorylation of AMOTp130 on S175 would be inhibitory on the direct interaction of AMOTp130 with F-actin in vitro. In contrast, we did not observe any interaction of AMOTp130 with monomeric G-actin by co-immunoprecipitation (Fig. 4F), suggesting that AMOTp130 specifically interacts with F-actin. These results indicate that AMOTp130 directly interacts with F-actin under negative regulation by phosphorylation of S175.

**Phosphorylation of AMOTp130 on S175 interferes with stress fiber and focal adhesion formation and inhibits endothelial cell migration**—AMOTp130 is known to directly bind and inhibit YAP (34, 43, 44). However, although AMOT-SA mutant show some decreased interaction with YAP, the interaction between YAP and wild-type AMOT is not significantly affected by AMOT phosphorylation (Fig. 4G). AMOT is also known for its roles in endothelial cell morphology and migration (47). Therefore we examined the function of AMOTp130 phosphorylation by Lats1/2 in endothelial cells. In agreement with our previous observations, knockdown of AMOT induces expression of YAP target genes CTGF and Cyr61 (Fig. 5A). Interestingly, consistent with a direct association of AMOT with F-actin, knockdown of AMOT leads to reduced stress fibers in cells, which also correlates with reduced focal adhesions (Fig. 5B, 5D). The defects are partially rescued by re-expression of AMOTp80 and better rescued by re-expression of AMOTp130 (Fig. 5B, 5D). Interestingly, co-expression of AMOTp130 wild-type or SA mutant but not the SD mutant together with AMOTp80 rescues stress fiber and focal adhesion formation to a level similar to control cells (Fig. 5B, 5D). Thus phosphorylation of AMOTp130 plays an inhibitory role on stress fiber and focal adhesion formation.

Remodeling of actin cytoskeleton and cell adhesion is crucial to cell migration. Consistent with alterations of the cytoskeleton and focal adhesions, knockdown of AMOT largely inhibits endothelial cell migration (Fig. 5C, 5E). Again, we observed that co-expression of AMOTp130 wild-type or SA mutant but not the SD mutant together with AMOTp80 rescues the cell migration defects (Fig. 5C, 5E). This suggests that phosphorylation of AMOT on S175 inhibits cell migration. We then further investigated the role of AMOT in cell migration downstream of the Hippo signaling. Serum starvation is well known to strongly inhibit cell migration in vitro. However, we found that cell migration in starvation condition is partially but significantly rescued by knockdown of Lats1 and Lats2 (Fig. 6A, 6C). This result suggests that activation of Lats1/2 by serum starvation due to blunted GPCR signaling is an important reason for repression of cell migration. More importantly, simultaneous knockdown of AMOT blocks cell migration induced by loss of Lats1/2 expression (Fig. 6A, 6C). Thus inhibition of the Hippo pathway leads to cell migration in an AMOT-dependent manner. In correlation with cell migration, knockdown of Lats1/2 also induces actin stress fiber and focal adhesion formation in serum starved cells in an AMOT-dependent manner (Fig. 6B, 6D). Our data suggest that AMOTp130 is important for endothelial cell
the Hippo pathway inhibits AMOT in cell migration

Phosphorylation of AMOTp130 on S175 inhibits angiogenesis in zebrafish- AMOT is known to control endothelial cell migration and angiogenesis in zebrafish (37). Thus we further investigated the effects of AMOTp130 phosphorylation on angiogenesis in zebrafish Tg(flk:GFP) transgenic embryos, in which GFP expression is driven by endothelial specific promoter flk. Consistent with the previous study (37), amot knockdown via injection of AMOT antisense morpholino-oligonucleotide (AMOT-MO) caused angiogenesis defects in AMOT morphants, in which intersegmental vessels (ISV) were disrupted and failed to reach the dorsolateral region at 30 hour post-fertilization (hpf) (Fig. 7-2). At 36 hpf, some ISV had still not arrived the most dorsolateral position so that the dorsal longitudinal anastomotic vessel (DLAV) formation was disrupted (Fig. 7-2). Nevertheless, the angiogenesis defects are rescued by co-injection of mRNAs encoding human AMOTp130 (Fig. 7-3) or the phospho-deficient SA mutant (Fig. 7-4) but not the phospho-mimetic SD mutant (Fig. 7-5). Furthermore, the angiogenic activity of AMOTp130 is inhibited by co-injection of mRNAs encoding Lats2 (Fig. 7-6) but not Lats2-KR (Fig. 7-7). In addition, the angiogenic activity of AMOTp130-SA is insensitive to Lats2 (Fig. 7-8). The overall development and morphologies of injected embryos were comparable to control embryos at bud stage and 30 hpf (data not shown). These results indicate that Lats2 could inhibit the angiogenic function of AMOTp130 in vivo through phosphorylation of S175.

**DISCUSSION**

Biological functions of kinases are largely determined by substrate selectivity. However, known substrates of the Lats1/2 kinases are very limited. Besides YAP/TAZ, several other proteins have been suggested as Lats1/2 substrates including Dyrk1a, MYPT1, and Snail1 (48-50). In this study, we identified AMOT family proteins to be new substrates of Lats1/2 with canonical target consensus motifs being phosphorylated by Lats1/2 to comparable levels as YAP/TAZ. Importantly, this phosphorylation is responsive to GPCR signaling and plays a regulatory role on AMOT interaction with F-actin thus regulates cell migration. While this manuscript is being prepared, an independent study reported the phosphorylation of AMOT by Lats1/2 in promoting AMOT-Lats1/2 interaction and its role in cell fate specification in preimplantation mouse embryos (51). Together, these studies suggest AMOT as an important effector of the Hippo pathway. We anticipate more substrates of Lats1/2 to be discovered to explain the ever expanding functions of the Hippo pathway.

AMOTp130 also plays a regulatory role in the Hippo pathway through both physical binding with YAP/TAZ and promotion of Lats1/2 activity (34,42-44). In addition, AMOT also interacts with Merlin, an upstream component of the Hippo pathway (40). We demonstrated that the association between wild-type AMOTp130 and YAP is not regulated by AMOTp130 phosphorylation. However, it was shown that the phospho-mimetic AMOTp130 has elevated interaction with Lats1/2 (51). Therefore there is possibly a feedback loop consisting of the two roles of AMOTp130 as both a regulator and an effector of the Hippo pathway, although the physiological context and the exact mechanism
the Hippo pathway inhibits AMOT in cell migration

would need further investigation. What we have found in this study also indicate that the phosphorylated and dephosphorylated AMOTp130 are both functional with differential roles. While the phosphorylated AMOT may promote Hippo signaling, the dephosphorylated AMOTp130 function as an F-actin interacting protein to promote stress fiber formation and cell migration.

YAP/TAZ are downstream effectors of the Hippo pathway and function through regulation of gene transcription (52). YAP/TAZ also promote cell migration likely through regulation of gene expression and initiation of an EMT program (53). However, our study identified AMOTp130 as a novel mediator of the Hippo pathway in inhibiting cell migration. Phosphorylation of AMOTp130 by Lats1/2 directly inhibits F-actin binding and correlates with reduced actin stress fiber and focal adhesion formation. Considering the direct role of F-actin and focal adhesion in cell migration, the role of AMOTp130 in cell migration is likely structural. Migration promoting functions of AMOT and YAP/TAZ could be reconciled in at least two ways. First, the expression pattern of AMOT and YAP/TAZ may dictate their functions in different tissues and cell types. Second, in cells expressing both of these proteins, AMOTp130 and YAP/TAZ may mediate acute and prolonged effects of the Hippo pathway on cell migration in a cooperative manner (Fig. 8). Whether YAP/TAZ play a role in endothelial cell migration is unknown. However, we demonstrated in this report that Lats1/2 play a role in endothelial cell migration in a manner dependent on AMOT phosphorylation. More importantly we demonstrated in vivo for the first time that the Hippo pathway may regulate developmental angiogenesis through AMOT phosphorylation. It would be interesting to investigate whether AMOT phosphorylation by the Hippo pathway also functions in pathological angiogenesis such as that in cancer.

Acknowledgements- We thank Dr. Bin Zhou for providing HUVEC cells. This work was supported by grants to Bin Zhao from National Natural Science Foundation of China (31271508), State Key Development Program for Basic Research of China (2013CB945303), Natural Science Foundation of Zhejiang (LR12C07001), and the Thousand Young Talents Plan of China.

REFERENCES
1. Zhao, B., Li, L., Lei, Q., and Guan, K. L. (2010) *Genes Dev* **24**, 862-874
2. Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S. A., Gayyed, M. F., Anders, R. A., Maitra, A., and Pan, D. (2007) *Cell* **130**, 1120-1133
3. Zhou, D., Conrad, C., Xia, F., Park, J. S., Payer, B., Yin, Y., Lauwers, G. Y., Thasler, W., Lee, J. T., Avruch, J., and Bardeesy, N. (2009) *Cancer Cell* **16**, 425-438
4. Camargo, F. D., Gokhale, S., Johnnidis, J. B., Fu, D., Bell, G. W., Jaenisch, R., and Brummelkamp, T. R. (2007) *Curr Biol* **17**, 2054-2060
5. Wu, S., Huang, J., Dong, J., and Pan, D. (2003) *Cell* **114**, 445-456
6. Jia, J., Zhang, W., Wang, B., Trinko, R., and Jiang, J. (2003) *Genes Dev* **17**, 2514-2519
7. Harvey, K. F., Pfleger, C. M., and Hariharan, I. K. (2003) *Cell* **114**, 457-467
the Hippo pathway inhibits AMOT in cell migration

8. Udan, R. S., Kango-Singh, M., Nolo, R., Tao, C., and Halder, G. (2003) *Nature cell biology* **5**, 914-920
9. Pantalacci, S., Tapon, N., and Leopold, P. (2003) *Nature cell biology* **5**, 921-927
10. Tapon, N., Harvey, K. F., Bell, D. W., Wahrer, D. C., Schiripo, T. A., Haber, D. A., and Hariharan, I. K. (2002) *Cell* **110**, 467-478
11. Justice, R. W., Zilian, O., Woods, D. F., Noll, M., and Bryant, P. J. (1995) *Genes Dev* **9**, 534-546
12. Xu, T., Wang, W., Zhang, S., Stewart, R. A., and Yu, W. (1995) *Development* **121**, 1053-1063
13. Kango-Singh, M., Nolo, R., Tao, C., Verstreken, P., Hiesinger, P. R., Bellen, H. J., and Halder, G. (2002) *Development* **129**, 5719-5730
14. Lai, Z. C., Wei, X., Shimizu, T., Ramos, E., Rohrbaugh, M., Nikolaidis, N., Ho, L. L., and Li, Y. (2005) *Cell* **120**, 675-685
15. Zhao, B., Li, L., Wang, L., Wang, C. Y., Yu, J., and Guan, K. L. (2012) *Genes Dev* **26**, 54-68
16. Yu, F. X., Zhao, B., Panupinstit, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., Fu, X. D., Mills, G. B., and Guan, K. L. (2012) *Cell* **150**, 780-791
17. Mo, J.-S., Yu, F.-X., Gong, R., Brown, J. H., and Guan, K.-L. (2012) *Genes & development* **26**, 2138-2143
18. Wada, K., Itoga, K., Okano, T., Yonemura, S., and Sasaki, H. (2011) *Development* **138**, 3907-3914
19. Sansores-Garcia, L., Bossuyt, W., Wada, K., Yonemura, S., Tao, C., Sasaki, H., and Halder, G. (2011) *EMBO J* **30**, 2325-2335
20. Fernandez, B. G., Gaspar, P., Bras-Pereira, C., Jezowska, B., Rebele, S. R., and Janody, F. (2011) *Development* **138**, 2337-2346
21. Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitii, S., Cordenonsi, M., Zancoatonato, F., Le Digabel, J., Forcatto, M., Bicciato, S., Elvassore, N., and Piccolo, S. (2011) *Nature* **474**, 179-183
22. Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenouve, T., Yu, J., Li, L., Zheng, P., Ye, K., Chinnaiyian, A., Halder, G., Lai, Z. C., and Guan, K. L. (2007) *Genes Dev* **21**, 2747-2761
23. Miller, E., Yang, J., DeRan, M., Wu, C., Su, A. I., Bonamy, G. M., Liu, J., Peters, E. C., and Wu, X. (2012) *Chemistry & biology* **19**, 955-962
24. Zhao, B., Li, L., Tumaneng, K., Wang, C. Y., and Guan, K. L. (2010) *Genes Dev* **24**, 72-85
25. Hao, Y., Chun, A., Cheung, K., Rashidi, B., and Yang, X. (2008) *J Biol Chem* **283**, 5496-5509
26. Lei, Q. Y., Zhang, H., Zhao, B., Zha, Z. Y., Bai, F., Pei, X. H., Zhao, S., Xiong, Y., and Guan, K. L. (2008) *Mol Cell Biol* **28**, 2426-2436
the Hippo pathway inhibits AMOT in cell migration

27. Chan, S. W., Lim, C. J., Guo, K., Ng, C. P., Lee, I., Hunziker, W., Zeng, Q., and Hong, W. (2008) *Cancer Res* **68**, 2592-2598
28. Yang, X., Yu, K., Hao, Y., Li, D. M., Stewart, R., Insogna, K. L., and Xu, T. (2004) *Nature cell biology* **6**, 609-617
29. Mikaeladze-Dvali, T., Wernet, M. F., Pistillo, D., Mazzoni, E. O., Teleman, A. A., Chen, Y. W., Cohen, S., and Desplan, C. (2005) *Cell* **122**, 775-787
30. Takahashi, A., Ohtani, N., Yamakoshi, K., Iida, S., Tahara, H., Nakayama, K., Nakayama, K. I., Ide, T., Saya, H., and Hara, E. (2006) *Nature cell biology* **8**, 1291-1297
31. Dutta, S., and Baehrecke, E. H. (2008) *Curr Biol* **18**, 1466-1475
32. Emoto, K., Parrish, J. Z., Jan, L. Y., and Jan, Y. N. (2006) *Nature* **443**, 210-213
33. McPherson, J. P., Tamblyn, L., Elia, A., Migon, E., Shehabeldin, A., Matysiak-Zablocki, E., Lemmers, B., Salmena, L., Hakem, A., Fish, J., Kassam, F., Squire, J., Bruneau, B. G., Hande, M. P., and Hakem, R. (2004) *Embo J* **23**, 3677-3688
34. Zhao, B., Li, L., Lu, Q., Wang, L. H., Liu, C. Y., Lei, Q., and Guan, K. L. (2011) *Genes Dev* **25**, 51-63
35. Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B., and Schilling, T. F. (1995) *Dev Dyn* **203**, 253-310
36. Cross, L. M., Cook, M. A., Lin, S., Chen, J. N., and Rubinstein, A. L. (2003) *Arteriosclerosis, thrombosis, and vascular biology* **23**, 911-912
37. Aase, K., Ernkvist, M., Ebarasi, L., Jakobsson, L., Majumdar, A., Yi, C., Birot, O., Ming, Y., Kvanta, A., Edholm, D., Aspenstrom, P., Kissil, J., Claesson-Welsh, L., Shimono, A., and Holmgren, L. (2007) *Genes Dev* **21**, 2055-2068
38. Zhong, T. P., Childs, S., Leu, J. P., and Fishman, M. C. (2001) *Nature* **414**, 216-220
39. Wells, C. D., Fawcett, J. P., Traweger, A., Yamanaka, Y., Goudreault, M., Elder, K., Kulkarni, S., Gish, G., Virag, C., Lim, C., Colwill, K., Starostine, A., Metalnikov, P., and Pawson, T. (2006) *Cell* **125**, 535-548
40. Yi, C., Troutman, S., Fera, D., Stemmer-Rachamimov, A., Avila, J. L., Christian, N., Persson, N. L., Shimono, A., Speicher, D. W., Marmorstein, R., Holmgren, L., and Kissil, J. L. (2011) *Cancer Cell* **19**, 527-540
41. Ranahan, W. P., Han, Z., Smith-Kinnaman, W., Nabinger, S. C., Heller, B., Herbert, B. S., Chan, R., and Wells, C. D. (2011) *Cancer Res* **71**, 2203-2211
42. Paramasivam, M., Sarkeshik, A., Yates, J. R., 3rd, Fernandes, M. J., and McCollum, D. (2011) *Molecular biology of the cell* **22**, 3725-3733
43. Oka, T., Schmitt, A. P., and Sudol, M. (2012) *Oncogene* **31**, 128-134
44. Wang, W., Huang, J., and Chen, J. (2011) *J Biol Chem* **286**, 4364-4370
45. Shah, K., and Shokat, K. M. (2003) *Methods Mol Biol* **233**, 253-271
46. Ernkvist, M., Aase, K., Ukomadu, C., Wohlschlegel, J., Blackman, R., Veitonmaki, N., Bratt, A., Dutta, A., and Holmgren, L. (2006) *FEBS J* **273**, 2000-2011
the Hippo pathway inhibits AMOT in cell migration

47. Ernkvist, M., Birot, O., Sinha, I., Veitonmaki, N., Nystrom, S., Aase, K., and Holmgren, L. (2008) Biochim Biophys Acta 1783, 429-437

48. Tschop, K., Conery, A. R., Litovchick, L., Decaprio, J. A., Settleman, J., Harlow, E., and Dyson, N. (2011) Genes Dev 25, 814-830

49. Chiyoda, T., Sugiyama, N., Shimizu, T., Naoe, H., Kobayashi, Y., Ishizawa, J., Arima, Y., Tsuda, H., Ito, M., Kaibuchi, K., Aoki, D., Ishihama, Y., Saya, H., and Kuninaka, S. (2012) J Cell Biol 197, 625-641

50. Zhang, K., Rodriguez-Aznar, E., Yabuta, N., Owen, R. J., Mingot, J. M., Nojima, H., Nieto, M. A., and Longmore, G. D. (2012) EMBO J 31, 29-43

51. Hirate, Y., Hirahara, S., Inoue, K., Suzuki, A., Alarcon, V. B., Akimoto, K., Hirai, T., Hara, T., Adachi, M., Chida, K., Ohno, S., Marikawa, Y., Nakao, K., Shimono, A., and Sasaki, H. (2013) Curr Biol 23, 1181-1194

52. Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Lin, J. D., Wang, C. Y., Chinnaiyan, A. M., Lai, Z. C., and Guan, K. L. (2008) Genes Dev 22, 1962-1971

53. Overholtzer, M., Zhang, J., Smolen, G. A., Muir, B., Li, W., Sgroi, D. C., Deng, C. X., Brugge, J. S., and Haber, D. A. (2006) Proc Natl Acad Sci U S A 103, 12405-12410
FIGURE LEGENDS

FIGURE 1. The Hippo pathway phosphorylates angiomotin family proteins. (A) Lats2 induces mobility shift of AMOT family proteins. HEK293 cells were transfected with plasmids encoding Flag-YAP or AMOT family proteins with or without Lats2 co-transfection. Cell lysates were resolved on Phos-tag-containing gels. Vps34 is a negative control. (B) Phosphatase eliminates AMOT mobility shift induced by Lats2. Flag-AMOTp130 was immunoprecipitated from transfected cells and treated with lambda protein phosphatase as indicated. Samples were analyzed as that in A. (C) Hippo pathway proteins synergistically induces AMOTp130 mobility shift. Lysates of transfected cells were resolved on Phos-tag-containing gels for mobility shift of Flag-AMOTp130. (D) Lats2 phosphorylates AMOTp130 in vitro. In vitro phosphorylation of GST-AMOTp130 by immunoprecipitated Lats2 was performed. (S), short exposure; (L), long exposure.

FIGURE 2. AMOTp130 is phosphorylated on S175 by Lats1/2 in response to GPCR signaling. (A) Domain organization of AMOTp130 and alignment of AMOT family proteins from different species. (B) Phosphorylation of S175 leads to Lats2-induced AMOTp130 up-shift. Lysates of transfected HEK293 cells were analyzed by western blots. (C) S175 of AMOTp130 is phosphorylated by Lats2. AMOTp130 phosphorylation was detected by pAMOT (S175)-specific antibody. (D) Lats2 phosphorylates AMOTp130 on S175 in vitro. Experiments were similar to that in Fig. 1D except that regular ATP was used. (E) Serum inhibits phosphorylation of endogenous AMOTp130 on S175. Serum-starved 293T cells were stimulated with 10% FBS for the indicated time before harvest. (F) LPA inhibits phosphorylation of endogenous AMOTp130 on S175. Serum-starved 293T cells were stimulated with serum or LPA for 1 hour before harvest. (G) GPCR signaling inhibits S175 phosphorylation of endogenous AMOTp130. 293T cells were transfected with indicated plasmids and serum starved overnight before harvest. (H) Knockdown of Lats1 and Lats2 represses endogenous AMOTp130 phosphorylation on S175. HEK293T cells were transfected with scramble or Lats1 and Lats2-specific siRNAs. Cells were serum starved overnight before harvest. (I) Disruption of F-actin induces phosphorylation of AMOTp130. HEK293T cells cultured in serum-rich medium were treated with 1μg/ml Latrunculin B (LatB) for 1h as indicated before being harvested for western blot analysis.

FIGURE 3. Phosphorylation of AMOTp130 on S175 inhibits interaction with F-actin. (A) Lats2 inhibits colocalization of AMOTp130 with F-actin. Transfected Cos7 cells were stained with anti-Flag antibody for localization of AMOTp130, AlexaFluor488-Phalloidin for F-actin, and DAPI for cell nuclei. (B) Colocalization of AMOTp130 with F-actin in digitonin-treated cells. Flag-AMOTp130 transfected Cos7 cells were treated with digitonin before fixation and stained as that in A. (C) AMOT-F-actin filaments are anchored to focal adhesions. Cos7 cells expressing wild-type or mutant AMOTs were co-stained with anti-Flag for AMOT and anti-vinculin to visualize focal adhesions. (D) Phospho-deficient mutant of AMOTp130 constitutively colocalizes with F-actin. Experiments were similar to these in A except the use of S175A mutant. (E) Phospho-mimetic mutant of AMOTp130 loses colocalization with F-actin. Experiments were similar to these in A except the use of S175D mutant. (F) Quantification of
AMOT-F-actin colocalization. 120 cells were quantified for each transfection. Thick filament is similar to Fig. 3A middle panel; thin filament is similar to that in Fig. 3A top panel; non filamentous is similar to that in Fig. 3E top panel.

FIGURE 4. Phosphorylation inhibits endogenous AMOTp130-F-actin interaction and direct AMOTp130-F-actin interaction in vitro. (A) Endogenous AMOT colocalizes with F-actin. Scramble or AMOT-specific siRNA transfected HEK293T cells were stained with anti-AMOT antibody #1 for localization of endogenous AMOTp130, AlexaFluor488-Phalloidin for F-actin, and DAPI for cell nuclei. (B) Endogenous AMOT colocalizes with F-actin. Experiments were similar to these in A except that endogenous AMOT was stained with anti-AMOT antibody #2. (C) Lats2 inhibits AMOT colocalization with F-actin in a kinase-dependent manner. HA-Lats2 wild-type or KR transfected HEK293T cells were stained with anti-AMOT antibody #1 for localization of endogenous AMOTp130 and anti-HA for Lats2 expression. (D) Quantification of filamentous localization of endogenous AMOT. Cells with or without filamentous AMOT in A and C were quantified. 120 cells were quantified for each sample. (E) Phospho-mimetic mutation inhibits AMOTp130 association with F-actin in vitro. Recombinant GST-AMOT wild-type or N-terminal fragment (N) were subjected to in vitro actin spin-down assay. (S), supernatant; (P), pellet. Actin was examined by Coomassie Blue staining and GST-AMOT was determined by western blots. Asterisks denote non-specific proteins. (F) AMOTp130 does not co-immunoprecipitate with G-actin. HEK293 cells were transfected as indicated. Transfection amount was adjusted to make soluble AMOT levels comparable. Lysates were immunoprecipitated with anti-Flag antibody. The presence of endogenous actin and Flag-AMOTp130 in immunoprecipitates and lysates were examined by western blots. (G) Phosphorylation of wild-type AMOTp130 by Lats2 does not affect interaction between AMOTp130 and YAP. HEK293 cells were transfected as indicated. AMOTp130 was immunoprecipitated with anti-HA antibody. Co-immunoprecipitation of YAP wild-type or 5SA mutant was examined by anti-Flag western blots. AMOTp130 phosphorylation was shown by electrophoretic mobility shift on Phos-tag containing gel.

FIGURE 5. Phosphorylation of AMOTp130 on S175 inhibits endothelial cell migration. (A) The knockdown efficiency of AMOT siRNAs. AMOT, CTGF, and Cyr61 levels in siRNA transfected HUVEC cells were determined by realtime RT-PCR. (B) Phospho-mimetic mutant of AMOT is unable to compensate endogenous AMOT in actin stress fiber and focal adhesion formation. Control or AMOT-expressing stable cells transfected with siRNAs were serum starved overnight and then seeded on fibronectin coated coverslips for 2 hours in serum-containing medium. Focal adhesions and F-actin were stained with anti-vinculin and AlexaFluor488-Phalloidin respectively. (C) Phospho-mimetic AMOT mutant could not rescue cell migration defects caused by loss of AMOT. Cells the same as these in B were examined in transwell migration assay. (D) The size of 60 FAs from the staining of each stable cell as these in B was quantified by ImageJ and drawn into scatter plot. The median number was indicated. (E) The number of migrated cells in C was quantified. Experiments were in duplicates.
FIGURE 6. Knockdown of Lats1/2 induces cell migration, actin stress fiber and focal adhesion in an AMOT-dependent manner. (A) Lats1/2 plays a role in serum deprivation-induced migration retardation by repressing AMOT. siRNA transfected HUVEC cells were serum starved and then seeded in transwell inserts in serum-free medium. The lower chambers were filled with serum-containing or serum-free medium as indicated. Cells on bottom sides of the transwells were stained after 12 hours. (B) Lats1/2 plays a role in serum deprivation-induced stress fiber and focal adhesion deformation by repressing AMOT. Cells were the same as these in A. Cells were serum starved overnight and then seeded on fibronectin coated coverslips for 2 hours either in serum-containing medium or serum-free medium as indicated. Focal adhesions and F-actin were stained with anti-vinculin and AlexaFluor488-Phalloidin respectively. (C) The number of migrated cells in A was quantified. Experiments were in duplicates. (D) The size of 25 FAs from the staining of each stable cell as these in B was quantified by ImageJ and drawn into scatter plot. The median number was indicated.

FIGURE 7. Phosphorylation of AMOTp130 by Lats1/2 regulates angiogenesis in zebrafish. The fluorescent microscopy analyses revealed the development of ISV and DLAV at 30 hpf and 36 hpf in the trunk region of control Tg(flk:GFP) embryos and embryos injected with AMOT-MO or a combination of AMOT-MO and mRNAs encoding human AMOTp130, Lats2 or their mutants. Red asterisk: defective ISV; red arrow: defective DLAV. ISV: intersegmental vessels. DLAV: dorsal longitudinal anastomotic vessels. Embryos were orientated with anterior to the left. Histogram depicted the quantification of normal and angiogenesis defective embryos at 30hpf. n=embryo number.

FIGURE 8. A model of Lats1/2 in regulation of cell migration through phosphorylation of AMOT and YAP. Phosphorylation of AMOT by Lats1/2 inhibits F-actin association and then actin stress fiber and focal adhesion formation. These effects of AMOT on cell structure and cell adhesion may work independently or in cooperation with YAP-dependent gene transcription alteration downstream of Lats1/2 to regulate cell migration.
Dai_Fig1.

A

|          | YAP | AMOT p130 | AMOTL1 | AMOTL2 | Vps34 |
|----------|-----|-----------|--------|--------|-------|
| Lats2    |     |           |        |        |       |
|          |     |           |        |        |       |
| WB: Flag (Phos-tag) |     |           |        |        |       |

B

| HA-Lats2 | Flag-AMOTp130 | Lambda PPase |
|----------|---------------|--------------|
|          | +             | +            |
|          | +             | +            |
|          | +             | +            |

IP: Flag

HA-Lats2

lysate

C

| HA-Lats2 | Flag-Mst2 | HA-Mob | HA-SAV | Flag-AMOTp130 (S) (Phos-tag) |
|----------|-----------|-------|-------|-----------------------------|
|          | -         | -     | -     | +                           |
|          | +         | +     | -     | +                           |
|          | -         | -     | +     | +                           |

Flag-AMOTp130 (L) (Phos-tag)

| HA-Lats2 | Flag-Mst2 | HA-Mob | HA-SAV |
|----------|-----------|-------|-------|
|          | -         | -     | -     |
|          | +         | -     | +     |
|          | -         | +     | -     |

D

| HA-Lats2 | Flag-Mst2 | HA-Mob | HA-SAV | GST-AMOTp130 (Phos-tag) |
|----------|-----------|-------|-------|------------------------|
|          | -         | -     | -     | +                      |
|          | +         | +     | -     | +                      |
|          | -         | +     | -     | +                      |

GST-AMOTp130

| HA-Lats2 | Flag-Mst2 | HA-Mob | HA-Sav |
|----------|-----------|-------|-------|
|          | -         | -     | -     |
|          | +         | -     | -     |
|          | -         | +     | -     |
Dai_Fig4.

A) siRNA anti-AMOT #1 F-actin Merge
Scramble
AMOT

B) siRNA anti-AMOT #2 F-actin Merge
Scramble
AMOT

C) AMOT HA Merge

D) Graph showing percentage of Non-filamentous vs Filamentous

E) Table showing GST-AMOTp130 F-actin

F) Table showing IP: Flag Ly

G) Table showing Flag-YAP HA-AMOTp130 Flag-Lats2 Flag-MST2 Flag-YAP HA-AMOTp130 Flag-YAP HA-AMOTp130 Flag-Lats2 Flag-MST2

IP:HA Ly

Downloaded from http://www.jbc.org/ by guest on July 9, 2020
Dai_Fig7.

1. Control
2. AMOT MO
3. AMOT MO+ hAMOTp130
4. AMOT MO+ hAMOTp130-SA
5. AMOT MO+ hAMOTp130-SD
6. AMOT MO+ hAMOTp130 +Lats2
7. AMOT MO+ hAMOTp130 +Lats2-KR
8. AMOT MO+ hAMOTp130-SD +Lats2

Angiogenesis states

n= 86 25 55 52 31 74 60 27

Defective
Normal

DLAV
ISV

30hpf 36hpf
Dai_Fig8.
Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration and angiogenesis

Xiaoming Dai, Peilu She, Fangtao Chi, Ying Feng, Huan Liu, Daqing Jin, Yiqiang Zhao, Xiaocan Guo, Dandan Jiang, Kun-Liang Guan, Tao P. Zhong and Bin Zhao

J. Biol. Chem. published online October 8, 2013

Access the most updated version of this article at doi: 10.1074/jbc.M113.518019

Alerts:
  • When this article is cited
  • When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts